Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
fda
4
×
life sciences
national
4
×
national blog main
national top stories
new york blog main
boston blog main
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
europe blog main
indiana blog main
indiana top stories
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
allergan
amgen
biogen
boston top stories
cancer
deerfield management
eli lilly
europe top stories
gilead sciences
What
medicines
4
×
fda
new
bio
class
covid
ipo
migraine
nod
roundup
acquisitions
activity
adults
allergan
amgen
announced
approval
approvals
approved
biogen
candidates
ceo
clamped
collabs
daniel
deal
delays
developed
developing
drug
economic
fast
gets
gilead
gilead’s
head
help
including
introduce
isn’t
Language
unset
Current search:
medicines
×
national
×
fda
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines